VENTANA MET (SP44) RxDx Assay
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date May 14, 2025
What did the FDA approve?
FDA records P240037 as an original PMA application. The recorded decision is approval, dated May 14, 2025.
FDA approval order statement
Approval for the VENTANA MET (SP44) RxDx Assay. The device is a qualitative immunohistochemical assay using rabbit monoclonal anti-MET, clone SP44, intended for use in the assessment of MET protein in formalin-fixed, paraffin embedded (FFPE) non-squamous non-small cell lung cancer (NSCLC) specimens by light microscopy. This assay is for use with OptiView DAB IHC Detection Kit for staining on a BenchMark ULTRA or BenchMark ULTRA PLUS instrument.MET protein expression clinical cut-off is >= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining (3+) in non-squamous NSCLC. VENTANA MET (SP44) RxDx Assay is indicated as an aid in identifying non-squamous NSCLC patients who may be eligible for treatment with EMRELIS (telisotuzumab vedotin-tllv). The results of VENTANA MET (SP44) RxDx Assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information and proper controls.This product is intended for in vitro diagnostic (IVD) use.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- May 14, 2025
Regulatory record facts
- Identifier
- P240037
- Regulatory pathway
- Premarket approval application
- Product code
- SER
- Decision code
- APPR
- Decision date
- May 14, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, MET.
- Product code
- SER
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240037 received
Application receipt date recorded by FDA.
P240037 · FDA decision
APPR
P240037/S003 · Related supplement
VENTANA MET (SP44) RxDx Assay
Timeline entries are records held by MedtechLedger for P240037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VENTANA MET (SP44) RxDx AssayP240037/S003 | Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1910 E. Innovation Park Dr., Tucson, AZ, 85755
Sources and methodology
- Original FDA record: P240037
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records